This little peptide has been gaining popularity! I don’t know if it’s because we talk to most women in their 30s through 50s or if it’s being posted about, but orders for PT141 are sky rocketing. Unlike medications, - PT-141: Acts on the brain by stimulating melanocortin receptors (primarily MC4R), which are involved in sexual desire and arousal. It is designed to increase the desire for sex rather than simply improving physical blood flow. Potential benefits: - Increased sexual desire - More sexual thoughts or fantasies - Greater arousal - Improved responsiveness to intimacy - Increased satisfaction with sexual experiences Check comments for PT141 vs testosterone

I personally get extra energy from my peps, they make me feel good. However, I have hear a couple times people have experienced a “meh” feeling. From a metabolic practitioner, the "blah feeling" and low energy on GLP-1 is soo common, we actually call it anhedonia, when you lose your drive for most things you used to enjoy I think the problem is most people just want to push through it when it clearly affects your weight loss too, and some of my clients end up not exercising/getting all those healthy habits they'll need to eventually get off these meds. The specific kind of flatness that comes from GLP-1 is happening because of the dopamine downregulation. Because GLP-1s are designed to lower your food rewards, these molecules bind to your "dopamine senders" and lower the volume on overall joy that you receive for anything. Recent research is pretty clear on this, which is why semaglutide is now being studied for addiction, same pathway. And yes, it does affect everyone, but some people feel it less than the others, if you're feeling any of these: 1) You lost your "want" to do things 2) You find yourself procrastinating often 3) It became harder to stay focused and engaged 4) You don't feel motivated to exercise 5) Your energy levels became less stable 6) The exhaustion isn't fixed by sleep It's probably the dopamine pathway and not depression in the regular sense. Which is a really important distinction because antidepressants don't fix this, the SSRI route works on serotonin and the issue here is dopamine. Flat dopamine = no reward signal = nothing feels worth it. Even when objectively your life is going well. And the frustrating part is most doctors aren't trained to look for this with GLP-1 patients, they default to depression screening which misses the actual mechanism. So, the symptom gets labeled wrong and treated wrong. In my experience, what really helps are things that don't try to force your brain into making more dopamine, but those that make you feel the joy that is already there.

GREAT NEWS!! Big announcement! If you go to the site, you will see some of your favs have dropped in $!! Yup!! $20-$40 ⬇️⬇️⬇️ Check it out

Why 80% of Americans will LIKELY be on a GLP-1 within 5-10 years 👇🏻👇🏻👇🏻 Get ready to have your mind blown 🤯 The SELECT trial showed a 20% reduction in heart attacks, strokes, and cardiovascular death in people who didn't even have diabetes. That alone would justify mass adoption. Heart disease is still the #1 killer in this country. Then a JAMA Network Open study of over 840,000 breast cancer patients found GLP-1 use was linked to improved survival and reduced recurrence, especially for those with obesity or type 2 diabetes — enough to warrant further research. A newer study presented at ASCO 2026 found GLP-1 use linked to roughly 30% lower breast cancer risk across 111,000 women. And in women already diagnosed, those on a GLP-1 were reportedly far less likely to progress to stage 4. Why? Inflammation. GLP-1s lower systemic inflammation independent of weight loss — CRP drops, inflammatory cytokines drop. Chronic inflammation is the root driver of nearly every age-related disease, so this one lever touches almost everything downstream. The STEP-HFpEF trial showed major improvement in heart failure symptoms. The FLOW trial showed a 24% reduction in kidney disease progression. Heart, kidneys, vessels — all protected. The SURMOUNT-OSA trial showed tirzepatide cut sleep apnea events by up to 63%. No CPAP machine touches that. And better sleep cascades into better metabolism, mood, and cognition. Knee osteoarthritis pain dropped dramatically in the STEP 9 trial — far beyond what weight loss alone would predict. People are walking again. That anti-inflammatory effect appears to act directly on joint tissue. There are even early signals in autoimmune conditions. Patients with psoriasis, rheumatoid arthritis, lupus, and IBD are reporting flare reduction, likely through gut-immune axis modulation. And there's emerging data on addiction — alcohol, nicotine, gambling, opioids. GLP-1s appear to dampen the brain's reward loop. If even half of this pans out, it reshapes public health on a scale we haven't seen in a century.